Abstract 219P
Background
Tyrosine kinase inhibitor (TKI) combined with immune checkpoint inhibitor(ICI)had demonstrated efficacy as first-line therapy for mRCC patients(pts)in clinical trials. However, data on real-world outcomes were limited. Our study aimed to evaluate the effectiveness of tislelizumab plus TKI in pts with mRCC.
Methods
Demographic and clinicopathological data of pts with mRCC between July 2019 and November 2022 were retrospectively collected from Sun Yat-sen University Cancer Center. All pts received first-line treatment with TKI monotherapy (TKI group, mainly sunitinib) or tislelizumab plus TKI therapy (combination group,mainly plus axitinib). TKI group who failed first-line therapy received tislelizumab plus TKI as second-line regimen. Combination group who failed first-line therapy received TKI or ICI plus TKI as second-line regimen. Outcomes including the objective response rate (ORR), progression-free survival (PFS), PFS2 (defined as time from initial treatment to progression after first subsequent therapy or any-cause death.) and overall survival (OS) were calculated.
Results
Totally 136 pts were analyzed, with a median age of 57 (17-81) years. 72.1% were male, 71.3% had clear cell RCC, 78.8% had an IMDC intermediate/poor-risk disease, 62.5% had metastatic number≥2, metastatic organs included lung (47.1%), bone (27.9%), liver (13.2%) and brain (5.1%). The median follow-up was 26.4 (23.1-29.6) months. The combination group (n=61) had a significantly longer PFS compared with the TKI group (n=75) (median PFS (95% CI): 17.4 (13.9-20.9) vs 6.2 (5.5-6.9) months, P<0.001). Similarly, the PFS2 was longer in the combination group (median PFS2 (95% CI): 23.5 (7.7-39.3) vs 14.7 (11.1-18.3) months, P=0.011). Besides, ORR was remarkably improved in the combination group (44.3% vs 18.7%, P=0.001). Median OS was not reached for combination group and 42.9 months for TKI group (p = 0.081).
Conclusions
Our data demonstrated effectiveness of tislelizumab plus TKI as first-line treatment for mRCC pts in real world.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract